To analyze the role of IFNγ in the effect of activated T cell secretome on imatinib-treated CML cells, we performed IFNγ neutralization experiments on the JURL-MK1 CML cell line using conditioned medium of T cells enriched from PBMCs of healthy blood donors (Figure 1). Here, IFNG is linked to chronic myelogenous leukemia, BCR-ABL1 positive.